
Sponsored by Johnson & Johnson
Advertisement
Articles by Sponsored by Johnson & Johnson
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder
2
Mixed Results From Phase 3 Data for AR1001 in Alzheimer Disease
3
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
4
Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive Disorder
5


